Indegene Ltd

Indegene Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Indegene Ltd

₹ 500 0.87%
30 Apr - close price
indegene.com BSE: 544172 NSE: INDGN
About

Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]

Key Points

Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.

Website BSE NSE
  • Market Cap ₹ 12,039 Cr.
  • Current Price ₹ 500
  • High / Low ₹ 633 / 414
  • Stock P/E 29.0
  • Book Value ₹ 130
  • Dividend Yield 0.40 %
  • ROCE 18.8 %
  • ROE 14.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Working capital days have increased from 61.8 days to 120 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
632 608 636 673 673 676 687 720 756 761 804 942 1,003
535 511 515 524 534 548 561 589 608 606 664 783 840
Operating Profit 97 97 121 149 139 129 126 132 148 155 141 160 164
OPM % 15% 16% 19% 22% 21% 19% 18% 18% 20% 20% 17% 17% 16%
13 28 12 13 26 22 21 38 26 22 20 19 -10
Interest 12 13 12 12 12 12 4 3 3 4 4 5 7
Depreciation 20 20 20 18 18 20 19 20 21 22 23 40 42
Profit before tax 79 92 101 132 134 120 124 146 149 152 133 135 105
Tax % 38% 26% 25% 25% 29% 27% 26% 25% 21% 23% 23% 24% 24%
49 68 75 99 95 88 92 110 118 116 102 103 80
EPS in Rs 2.20 3.08 3.38 4.45 4.26 3.67 3.83 4.58 4.90 4.85 4.25 4.28 3.31
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
553 643 966 1,665 2,306 2,590 2,839 3,510
511 499 736 1,378 1,910 2,084 2,292 2,892
Operating Profit 42 144 230 287 396 505 548 619
OPM % 8% 22% 24% 17% 17% 20% 19% 18%
7 -102 -3 -21 58 79 94 52
Interest 6 9 7 6 31 49 22 19
Depreciation 17 19 26 33 60 76 80 126
Profit before tax 26 14 195 226 363 459 539 525
Tax % 45% 191% 23% 28% 27% 27% 25% 24%
14 -12 149 163 266 337 407 401
EPS in Rs 89.98 -40.20 951.96 937.73 11.99 15.14 16.95 16.65
Dividend Payout % 0% 0% 0% 0% 0% 0% 12% 13%
Compounded Sales Growth
10 Years: %
5 Years: 29%
3 Years: 15%
TTM: 24%
Compounded Profit Growth
10 Years: %
5 Years: 23%
3 Years: 16%
TTM: 0%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -6%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 19%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.31 0.31 0.31 0.35 44 44 48 48
Reserves 73 -105 324 764 1,020 1,385 2,568 3,091
147 483 51 66 502 490 102 144
108 222 220 524 638 627 609 1,337
Total Liabilities 329 600 596 1,353 2,204 2,546 3,326 4,620
104 119 86 138 664 646 678 1,812
CWIP 0 0 0 0 0 0 4 12
Investments 0 13 0 120 614 796 1,290 1,100
225 468 510 1,096 926 1,103 1,355 1,697
Total Assets 329 600 596 1,353 2,204 2,546 3,326 4,620

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
65 22 172 297 130 508 442 651
-18 -16 -81 -158 -896 -326 -677 -512
-21 136 -132 233 333 -66 288 -83
Net Cash Flow 25 143 -40 373 -433 115 52 56
Free Cash Flow 48 16 151 272 111 497 412 606
CFO/OP 196% 34% 96% 128% 60% 125% 110% 129%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 60 127 108 97 102 91 97 80
Inventory Days
Days Payable
Cash Conversion Cycle 60 127 108 97 102 91 97 80
Working Capital Days -7 -5 45 11 41 27 39 120
ROCE % 37% 55% 46% 33% 29% 25% 19%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024
Active Clients
Number

Log in to view insights

Please log in to see hidden values.

Login
Million Dollar Plus Clients (>$1M USD Revenue TTM)
Number
Total Employee Headcount
Number
Days Sales Outstanding (Net DSO)
Days
Voluntary Attrition (LTM)
Percentage
Delivery Employees with Healthcare Expertise
Percentage

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
3.79% 4.82% 5.03% 5.24% 10.04% 11.30% 11.48% 10.27%
3.84% 3.17% 3.99% 4.96% 7.20% 6.95% 8.06% 8.29%
92.38% 92.01% 91.01% 89.80% 82.75% 81.74% 80.44% 81.43%
No. of Shareholders 2,03,5991,51,4401,53,7891,44,7081,51,9971,51,8091,47,1821,42,119

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls